Literature DB >> 28857841

Vocal fold leukoplakia: incidence, management, and prevention.

Noah P Parker1.   

Abstract

PURPOSE OF REVIEW: The purpose of this article is to provide an update on English-language literature evaluating the current understanding of incidence, management, and prevention of vocal fold leukoplakia focusing on premalignancy. RECENT
FINDINGS: Recent studies have continued to try to elucidate factors influencing recurrence and progression of dysplastic disease, though results vary. Although advanced diagnostic techniques have attempted to predict disease behavior, tissue diagnosis continues to be essential. Studies reinforce the necessity of removal of disease as the primary treatment, whereas use of photoangiolytic lasers via the ablative technique has increased, as has transition of some patients into the office-based settings for treatment. Although genetic and molecular testing may hold promise for predictive purposes, further study is necessary, and chemotherapy for recalcitrant disease continues to be an area of study with few case studies being reported.
SUMMARY: Management of vocal fold leukoplakia continues to progress in terms of identification and treatment. Although many work to advance our knowledge in the field and push treatment strategies toward newer avenues, pathologic diagnosis, eradiation of disease on the basis of experience and skill, and close surveillance continue to be paramount.

Entities:  

Mesh:

Year:  2017        PMID: 28857841     DOI: 10.1097/MOO.0000000000000406

Source DB:  PubMed          Journal:  Curr Opin Otolaryngol Head Neck Surg        ISSN: 1068-9508            Impact factor:   2.064


  8 in total

1.  Elevated peripheral inflammatory markers are related with the recurrence and canceration of vocal fold leukoplakia.

Authors:  Yi Fang; Yue Yang; Min Chen; Peijie He; Lei Cheng; Jian Chen; Haitao Wu
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-31       Impact factor: 2.503

2.  Association of laryngeal cancer with vocal cord leukoplakia and associated risk factors in 1,184 patients diagnosed in otorhinolaryngology practices in Germany.

Authors:  Karel Kostev; Louis E C Jacob; Matthias Kalder; Andreas M Sesterhenn; David Ulrich Seidel
Journal:  Mol Clin Oncol       Date:  2018-03-21

3.  Flexible transnasal endoscopy with white light or narrow band imaging for the diagnosis of laryngeal malignancy: diagnostic value, observer variability and influence of previous laryngeal surgery.

Authors:  Nikolaos Davaris; Susanne Voigt-Zimmermann; Siegfried Kropf; Christoph Arens
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-19       Impact factor: 2.503

4.  Readability of Online Materials Related to Vocal Cord Leukoplakia.

Authors:  Matthew Shneyderman; Grace E Snow; Ruth Davis; Simon Best; Lee M Akst
Journal:  OTO Open       Date:  2021-08-09

5.  Genetic polymorphisms and protein levels in vocal fold leukoplakia: a systematic review.

Authors:  C P Campello; M F B Lima-Silva; E L S de Lima; G R S Nunes; H A M Silva; E Dellalibera; L R P B de Britto; C A A Lemos; M T C Muniz
Journal:  Braz J Med Biol Res       Date:  2022-03-11       Impact factor: 2.590

6.  Videolaryngoendoscopic and Stroboscopic Evaluation in Predicting the Malignancy Risk of Vocal Fold Leukoplakia.

Authors:  Agata Leduchowska; Joanna Morawska; Wioletta Pietruszewska
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

Review 7.  Laryngeal tuberculosis in renal transplant recipients: A case report and review of the literature.

Authors:  Fabrizio Cialente; Michele Grasso; Massimo Ralli; Marco De Vincentiis; Antonio Minni; Griselda Agolli; Michele Dello Spedale Venti; Mara Riminucci; Alessandro Corsi; Antonio Greco
Journal:  Bosn J Basic Med Sci       Date:  2020-08-03       Impact factor: 3.363

8.  The Variation of Peripheral Inflammatory Markers in Vocal Leukoplakia before and after Recurrence and Canceration.

Authors:  Yi Fang; Min Chen; Yue Yang; Jian Chen; Lei Cheng; Peijie He; Haitao Wu
Journal:  Dis Markers       Date:  2020-08-01       Impact factor: 3.434

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.